Entera Bio Ltd. EBITDA

EBITDA of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including EBITDA growth rates and interactive chart. Earnings before interest, tax, depreciation and amortization (EBITDA) is a measure of a company's operating performance. Essentially, it's a way to evaluate a company's performance without having to factor in depreciation, interest expenses (debt), writedowns or other accounting measures and taxes. EBITDA, however, can be misleading because it strips out the cost of capital investments like property, plant, and equipment. To calculate EBITDA, take operating profit (also called EBIT) and add back depreciation and amortization.

Highlights and Quick Summary

  • EBITDA for the quarter ending June 29, 2020 was $-3.48 Million (a 22.18% increase compared to previous quarter)
  • Year-over-year quarterly EBITDA increased by 25.22%
  • Annual EBITDA for 2019 was $-11.2 Million (a 3.78% increase from previous year)
  • Annual EBITDA for 2018 was $-10.8 Million (a -4.36% decrease from previous year)
  • Twelve month EBITDA ending June 29, 2020 was $-12.5 Million (a 13.72% increase compared to previous quarter)
  • Twelve month trailing EBITDA increased by 22.45% year-over-year
Trailing EBITDA for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
$-12.5 Million $-11 Million $-11.2 Million $-10.2 Million
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EBITDA of Entera Bio Ltd.

Most recent EBITDAof ENTX including historical data for past 10 years.

Interactive Chart of EBITDA of Entera Bio Ltd.

Entera Bio Ltd. EBITDA for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-3.48 $-2.85
2019 $-3.44 $-2.78 $-1.96 $-3.04 $-11.22
2018 $-2.47 $-2.86 $-1.35 $-4.14 $-10.81
2017 $-11.3

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.